Literature DB >> 12632498

A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma.

Chun-Hong Ma1, Wen-Sheng Sun, Pei-Kun Tian, Li-Fen Gao, Su-Xia Liu, Xiao-Yan Wang, Li-Ning Zhang, Ying-Lin Cao, Li-Hui Han, Xiao-Hong Liang.   

Abstract

AIM: To construct a novel HBV antisense RNA delivery system targeting hapatocellular carcinoma and study its inhibitory effect in vitro and in vivo.
METHODS: GE7,a 16-peptide specific to EGFR, and HA20,a homologue of N-terminus of haemagglutinin of influenza viral envelope protein, were synthesized and conjugated with polylysin. The above conjugates were organized into the pEBAF-as-preS2, a hepatocarcinoma specific HBV antisense expression vector, to construct a novel HBV antisense RNA delivery system, named AFP-enhancing 4-element complex. Hepatocelluar carcinoma HepG2.2.15 cells was used to assay the in vitro inhibition of the complex on HBV. Expression of HBV antigen was assayed by ELISA. BALB/c nude mice bearing HepG2.2.15 cells were injected with AFP-enhancing 4-element complex. The expression of HBV antisense RNA was examined by RT-PCR and the size of tumor in nude mice were measured.
RESULTS: The AFP-enhancing 4-element complex was constructed and DNA was completely trapped at the slot with no DNA migration when the ratio of polypeptide to plasmid was 1:1. The expression of HBsAg and HBeAg of HepG2.2.15 cells was greatly decreased after being transfected by AFP-enhancing 4-element complex. The inhibitory rates were 33.4 % and 58.5 % respectively. RT-PCR showed HBV antisense RNA expressed specifically in liver tumor cells of tumor-bearing nude mice. After 4 injections of AFP-enhancing 4-element complex containing 0.2 micro g DNA, the diameter of the tumor was 0.995 cm+/-0.35, which was significantly smaller than that of the control groups(2.215 cm+/-0.25, P<0.05).
CONCLUSION: AFP-enhancing 4-element complex could deliver HBV antisense RNA targeting on hepatocarcinoma and inhibit both HBV and liver tumor cells in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632498      PMCID: PMC4621562          DOI: 10.3748/wjg.v9.i3.463

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Current status of gene therapy in gastroenterology.

Authors:  Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

2.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  [Reversing malignant phenotypes of liver cancer cell lines with antisense gene to human telomerase reverse transcriptase].

Authors:  Shiming Yang; Dianchun Fang; Aimin Liu; Jinliang Yang; Yuanhui Luo; Rong Lu; Weiwen Liu
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2002-04

4.  Optimized regulation of gene expression using artificial transcription factors.

Authors:  Reza Yaghmai; Garry R Cutting
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

Review 5.  Development of long-circulating polyelectrolyte complexes for systemic delivery of genes.

Authors:  David Oupický; Manfred Ogris; Leonard W Seymour
Journal:  J Drug Target       Date:  2002-03       Impact factor: 5.121

6.  Current issues in cochlear gene transfer.

Authors:  Anil K Lalwani; Jussi Jero; Anand N Mhatre
Journal:  Audiol Neurootol       Date:  2002 May-Jun       Impact factor: 1.854

7.  Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice.

Authors:  X W Wang; J H Yuan; R G Zhang; L X Guo; Y Xie; H Xie
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

8.  Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis.

Authors:  Q H Nie; Y Q Cheng; Y M Xie; Y X Zhou; Y Z Cao
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

9.  Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy.

Authors:  B E Huber; C A Richards; T A Krenitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

10.  2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells.

Authors:  Noriyuki Yatabe; Satoru Kyo; Seiji Kondo; Taro Kanaya; Zhuo Wang; Yoshiko Maida; Masahiro Takakura; Mitsuhiro Nakamura; Masaaki Tanaka; Masaki Inoue
Journal:  Cancer Gene Ther       Date:  2002-07       Impact factor: 5.987

View more
  3 in total

1.  Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.

Authors:  Tong-Dong Shi; Yu-Zhang Wu; Zheng-Cai Jia; Wei Zhou; Li-Yun Zou
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  Antisense oligonucleotide targeting at the initiator of hTERT arrests growth of hepatoma cells.

Authors:  Su-Xia Liu; Wen-Sheng Sun; Ying-Lin Cao; Chun-Hong Ma; Li-Hui Han; Li-Ning Zhang; Zhen-Guang Wang; Fa-Liang Zhu
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  Expression of transforming growth factor-alpha and hepatitis B surface antigen in human hepatocellular carcinoma tissues and its significance.

Authors:  Jing Zhang; Wen-Liang Wang; Qing Li; Qing Qiao
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.